SCHEMBL21801541

SCHEMBL21801541

Fc1ccc(Nc2nnc(-c3cc4cc(Cl)ccc4[nH]3)o2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ QPCT Q16769 2/20 0.47
▸ MEN1 O00255 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ RXFP1 Q9HBX9 1/20 0.46
▸ GSK3B P49841 5/20 0.42
▸ NPC1 O15118 3/20 0.40
▸ RAB9A P51151 3/20 0.40
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ CYP19A1 P11511 1/20 0.40
▸ CNR2 P34972 1/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ BCL2 P10415 1/20 0.39
▸ VCP P55072 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21801697 0.88 RAB9A (0.51) QPCTMEN1KMT2AGSK3BNPC1
SCHEMBL21801490 0.76 QPCT (0.44) QPCTGSK3BNPC1RAB9AKDM4E
SCHEMBL21801558 0.74 CNR1 (0.43) QPCTGSK3BCNR2CA12CA1
SCHEMBL21801540 0.74 CDC7 (0.53) QPCTMEN1KMT2ANPC1RAB9A
SCHEMBL21801474 0.72 NPC1 (0.46) QPCTMEN1KMT2ANPC1RAB9A
SCHEMBL6585157 0.71 MEN1 (0.70) MEN1KMT2ARXFP1NPC1RAB9A
SCHEMBL29804879 0.71 MEN1 (0.70) MEN1KMT2ARXFP1NPC1RAB9A
SCHEMBL13171355 0.69 ACHE (0.67) QPCTMEN1KMT2AGSK3BNPC1
SCHEMBL30578675 0.67 KDM4E (0.40) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL30578666 0.67 THRB (0.45) MEN1KMT2ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220257569-A1 INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2022-08-18 — — US disclosed
WO-2020051707-A1 INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2020-03-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220257569-A1 INDOLE-OXADIAZOLE COMPOUNDS AND THEIR THERAPEUTIC USE CNR2, GPR119, CNR1 QPCT 2631/4885MEN1 4146/4885KMT2A 2952/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback